1 November 2020 in Drug Design, Development and Therapy
Purpose: Homoharringtonine (HHT) has been used as an antileukemia agent in the clinic which processes a high-potential therapeutic efficacy against multiple myeloma (MM). In this study, we investigated the antimyeloma mechanism of HHT. Methods: Three MM cell lines and a xenograft model were applied. Mitochondrial function was evaluated by detecting MitoTracker Green, the mtDNA copy number, mitochondrial protein and enzyme activity, the mitochondrial membrane potential and mitochondrial morphology. Mitophagy levels were assessed by monitoring autophagosomes, performing a colocalization analysis and determining the levels of related proteins. An shRNA was applied to knockdown Parkin. Results: Based on the results of the in vitro experiments, HHT exerted a promising antiproliferative effect on the MM.1S, RPMI 8226 and H929 cell lines by increasing mitophagy. In addition, HHT markedly inhibited myeloma tumor growth and prolonged survival by promoting mitophagy in vivo. Furthermore, HHT treatment contributed to notable mitochondrial dysfunction and Parkin-dependent mitophagy, as evidenced by the destruction of mitochondria, the decrease in the mtDNA copy number, decrease in the Bcl-2/Bax ratio, and decrease in the levels of mitochondrial proteins and the optimal expression of Parkin and NDP52. However, the addition of rapamycin did not produce significant synergistic effect with HHT, indicating that HHT reached the threshold level to induce mitophagy. The colocalization analysis and assessment of mitochondrial function examination further confirmed that HHT triggered mitophagy and mitochondrial dysfunction. Moreover, the antiproliferative effect of HHT was reversed by an shRNA targeting Parkin, highlighting the indispensable role of Parkin-dependent mitophagy in the antimyeloma effect of HHT. Conclusion: HHT exerts an antimyeloma effect by inducing excess mitophagy, providing new mechanistic insights into a therapeutic strategy for MM.
1 March 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Background: Glyphosate has raised health concerns due to its widespread detection in environment and human tissues. Limited evidence exists found in the association between urinary glyphosate concentrations and chronic obstructive pulmonary disease. Methods: Analyzing data from 2588 participants, we applied survey-weighted logistic regression models and cubic spline techniques to quantify link between urinary glyphosate concentrations and prevalence of COPD. Further subgroup and sensitivity analyses were also conducted. Results: Study revealed a significant association between higher urinary glyphosate concentrations that increased risk of COPD. In fully adjusted models, a one-unit increase in natural logarithm of urinary glyphosate was associated with a 35% increased risk of COPD (OR, 1.35, 95% CI, 1.01– 1.82, P=0.043). Subgroup analyses showed consistent associations across different demographic groups with a pronounced association in current smokers and females. Sensitivity analyses and exclusion of participants with chronic kidney disease reinforced the robustness of the findings. Conclusion: Findings provide evidence of a positive association between urinary glyphosate concentrations and prevalence of COPD in a representative sample of the adult population at the United States of America. Further studies are needed to investigate the influence of factors and other environmental pollutants on COPD.
1 May 2019 in Biochemical and Biophysical Research Communications